Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Sell
13
MBRX Quote, Financials, Valuation and Earnings
Last price:
$0.30
Seasonality move
:
6.94%
Day range:
$0.26 - $0.28
52-week range:
$0.25 - $4.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
92.13x
Volume:
5.8M
Avg. volume:
1.6M
1-year change:
-92.68%
Market cap:
$3.9M
Revenue:
--
EPS (TTM):
-$4.73
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Moleculin Biotech has 3307.57% upside to fair value with a price target of $9.33 per share.
MBRX vs. S&P 500
-
Over the past 5 trading days, Moleculin Biotech has underperformed the S&P 500 by -57.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Moleculin Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Moleculin Biotech has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Moleculin Biotech reported revenues of --.
Earnings Growth
-
Moleculin Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Moleculin Biotech reported earnings per share of -$0.69.
Enterprise value:
-3.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$31.9M | -$28M | -$25.9M | -$6.7M | -$5.9M | |
| EBITDA | -$31.8M | -$27.8M | -$25.8M | -$6.6M | -$5.9M | |
| Diluted EPS | -$15.83 | -$12.99 | -$4.73 | -$2.02 | -$0.69 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $88M | $67.3M | $39.3M | $19M | $9.3M | |
| Total Assets | $99.8M | $78.8M | $51.1M | $30.8M | $21M | |
| Current Liabilities | $4.6M | $4.8M | $5M | $5.4M | $6.9M | |
| Total Liabilities | $11.3M | $6.1M | $5.4M | $9.3M | $21M | |
| Total Equity | $88.5M | $72.7M | $45.7M | $21.6M | $42K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.9M | -$24.3M | -$21.7M | -$6.7M | -$4.6M | |
| Cash From Investing | -- | -$124K | -$13K | -- | -- | |
| Cash From Financing | $118K | $4M | $12.6M | -- | $8M | |
| Free Cash Flow | -$28.9M | -$24.4M | -$21.7M | -$6.7M | -$4.6M | |
MBRX
Sector
Market Cap
$3.9M
$32.8M
Price % of 52-Week High
5.82%
46.28%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-92.68%
-35.38%
Beta (5-Year)
1.562
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.56
200-day SMA
Sell
Level
$1.66
Bollinger Bands (100)
Sell
Level
0.71 - 1.29
Chaikin Money Flow
Sell
Level
-167M
20-day SMA
Sell
Level
$0.71
Relative Strength Index (RSI14)
Sell
Level
18.56
ADX Line
Sell
Level
38.55
Williams %R
Buy
Level
-96.2656
50-day SMA
Sell
Level
$0.87
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
241.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Stock Forecast FAQ
In the current month, MBRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBRX average analyst price target in the past 3 months is $9.33.
-
Where Will Moleculin Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Moleculin Biotech share price will rise to $9.33 per share over the next 12 months.
-
What Do Analysts Say About Moleculin Biotech?
Analysts are divided on their view about Moleculin Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moleculin Biotech is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Moleculin Biotech's Price Target?
The price target for Moleculin Biotech over the next 1-year time period is forecast to be $9.33 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MBRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Moleculin Biotech is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MBRX?
You can purchase shares of Moleculin Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moleculin Biotech shares.
-
What Is The Moleculin Biotech Share Price Today?
Moleculin Biotech was last trading at $0.30 per share. This represents the most recent stock quote for Moleculin Biotech. Yesterday, Moleculin Biotech closed at $0.27 per share.
-
How To Buy Moleculin Biotech Stock Online?
In order to purchase Moleculin Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Howard Marks Buy Grab Stock?
When a legendary value investor who cut his teeth in…
Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 3.18% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 2.26% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 13.99% over the past day.
